Niraparib

Niraparib is a 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy. Among its listed roles, it functions as a antineoplastic agent, an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor, a radiosensitizing agent and an apoptosis inducer. It is grouped under the following drug class(es): Antineoplastic agents and PARP Inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include niraparibum and 2-(4-((3S)-piperidin-3-yl)phenyl)indazole-7-carboxamide. Its PubChem CID is 24958200.

CAS No 1038915-60-4
Molecular Formula C19H20N4O
Molecular Weight 320.4 g/mol
Synonyms 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide

Frequently Asked Questions